Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Interk Peptide Therapeutics Limited is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently recorded. This single action is assigned to 1 distinct examiner, reflecting a focused point of contact within the patent office. The prosecution is localized within 1 distinct art unit, which suggests the company's peptide technology falls under a specific specialized classification. This concentration of activity in a single unit simplifies the administrative tracking for the portfolio at this stage.
The busiest examiner for the company is VARADARAJ, ARCHANA, who is handling 1 busiest examiner pending office action. Because the total number of pending office actions is also 1, this examiner is responsible for the entirety of the company's current workload. Practitioners should note that the outcome of the company's current prosecution efforts depends entirely on the interaction with this one individual. The presence of 1 distinct examiner and 1 distinct art unit indicates a very targeted technical focus for the company's current filings. The results of this 1 pending office action will be the primary indicator of success in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684922 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNITY, INCLUDING AUTOIMMUNITY ASSOCIATED WITH CANCER AND CANCER THERAPY | VARADARAJ, ARCHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684922 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNITY, INCLUDING AUTOIMMUNITY ASSOCIATED WITH CANCER AND CANCER THERAPY | VARADARAJ, ARCHANA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684922 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNITY, INCLUDING AUTOIMMUNITY ASSOCIATED WITH CANCER AND CANCER THERAPY | VARADARAJ, ARCHANA | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInterk Peptide Therapeutics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Archana Varadaraj has the most, with 1 of Interk Peptide Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
